BioPharmSignal logoBioPharmSignal

Biotech News

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid (PYPD)PolyPidFDA / regulatory

PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative

Related news

PYPDPolyPid2025-12-03 13:30 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

View all latest news

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control...

Recent company news

PYPDPolyPid2026-10-01 13:15 EST

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

PYPDPolyPid2026-10-01 12:56 EST

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

PYPDPolyPid2026-09-15 12:30 EST

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PYPDPolyPid2026-08-12 11:30 EST

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PYPDPolyPid2026-07-30 12:00 EST

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Stock data

Close
5.19 USD
Market cap
93.38M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States